当前位置:科学网首页 > 小柯机器人 >详情
BNT162b2疫苗诱导的人类血清能够中和SARS-CoV-2突变株B.1.1.7伪病毒
作者:小柯机器人 发布时间:2021/2/2 11:12:09

德国BioNTech公司Ugur Sahin研究团队发现,BNT162b2疫苗诱导的人类血清能够中和SARS-CoV-2突变株B.1.1.7伪病毒。这一研究成果于2021年1月29日在线发表在国际学术期刊《科学》上。

研究人员表示,英国最近出现了一种新的SARS-CoV-2突变株,称为B.1.1.7(VOC 202012/01),据报道比其他毒株传播得更快、更高效。该变体具有异常大量的突变,其刺突蛋白的氨基酸变化为10个,从而引发了大众对中和抗体有效性的担忧。

研究人员测试了早期参考株或B.1.1.7突变株的SARS-CoV-2-S伪病毒与40名志愿者血清的反应,这些志愿者在先前的COVID-19 mRNA疫苗(BNT162b2)试验中进行了疫苗接种。免疫血清略有降低,但总体上保留了针对B.1.1.7突变株假病毒的中和效价。这些数据表明B.1.1.7突变株不会逃逸BNT162b2介导的保护作用。 

附:英文原文

Title: Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

Author: Alexander Muik, Ann-Kathrin Wallisch, Bianca Snger, Kena A. Swanson, Julia Mühl, Wei Chen, Hui Cai, Daniel Maurus, Ritu Sarkar, zlem Türeci, Philip R. Dormitzer, Uur ahin

Issue&Volume: 2021/01/29

Abstract: Recently, a new SARS-CoV-2 lineage called B.1.1.7 (variant of concern: VOC 202012/01) emerged in the United Kingdom that was reported to spread more efficiently and faster than other strains. This variant has an unusually large number of mutations with 10 amino acid changes in the spike protein, raising concerns that its recognition by neutralizing antibodies may be affected. Here, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.

DOI: 10.1126/science.abg6105

Source: https://science.sciencemag.org/content/early/2021/01/28/science.abg6105

 

期刊信息
Science:《科学》,创刊于1880年。隶属于美国科学促进会,最新IF:41.037